MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today announced that the first patient has been dosed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback